Skip to main content
Publications
Brufsky A, Sandin R, Stergiopoulos S, Chen C, Karanth S, Li B, Esterberg L, Makari D, Candrilli S, Goyal R, Rugo H. Overall survival with palbociclib (PAL) plus an aromatase inhibitor (AI) versus AI alone in older patients (pts) with de novo, HR+/HER2− metastatic breast cancer: a SEER-Medicare analysis. Poster presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting; May 31, 2024. Chicago, IL.
Melgar M, Abrams JY, Godfred-Cato S, Shah AB, Garg A, Strunk A, Narasimhan M, Koptyev J, Norden A, Musheyev D, Rashid F, Tannenbaum R, Estrada-Y-Martin RM, Patel B, Karanth S, Achenbach CJ, Hall GT, Hockney SM, Caputo M, Abbo LM, Beauchamps L, Morris SB, Cifuentes RO, de St Maurice A, Bell DS, Prabaker KK, Sanz Vidorreta FJ, Bryant E, Cohen DK, Mohan R, Libby CP, SooHoo S, Domingo TJ, Campbell AP, Belay ED. A multicenter retrospective cohort study to characterize patients hospitalized with MIS-A and COVID-19 in the United States, 2020-2021. Clin Infect Dis. 2023 Nov 17;77(10):1395-405. doi: 10.1093/cid/ciad374
Weber JS, Haque W, Markovic SN, Salama AKS, Mehmi I, Sullivan RJ, Najjar YG, Van Akkool A, Menzies A, Long G, Taylor AM, Haanen J, Zijlker L, Davis KL, Karanth S, Shah RM, Connolly L, Norton D. Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant checkpoint inhibitor and subsequent surgical resection in patients with BRAF V600–mutated stage III/IV melanoma. Poster presented at the ESMO Congress 2023; October 22, 2023. Madrid, Spain.
Furqan M, Karanth S, Goyal RK, Shih Y, Cai B, Rombi J, Davis KL, Caro N, Saliba TR. Real-world assessment of treatment effectiveness in patients with advanced non-small cell lung cancer (aNSCLC) with MET exon 14 skipping (METex14). Poster presented at the 2023 ASCO Annual Meeting; June 2, 2023. Chicago, IL. [abstract] J Clin Oncol. 2023; 4((Suppl 16):e21112.
Adrianzen Herrera D, Pradhan K, Snyder R, Karanth S, Janakiram M, Mantzaris I, Braunschweig I, Budhathoki A, Shah UA, Verma AK, Murthy SB, Shastri A. Myelodysplastic syndromes and the risk of cardiovascular disease in older adults: A SEER-Medicare analysis. Leukemia. 2020 Jun;34(6):1689-93. doi: 10.1038/s41375-019-0673-8
Adrianzen Herrera D, Pradhan K, Snyder R, Karanth S, Janakiram M, Mantzaris I, Murthy S, Verma A, Shastri A. Myelodysplastic Syndromes (MDS) are an independent risk factor for an earlier onset of myocardial infarction and increased mortality from Cardiovascular Disease (CVD). Poster presented at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition; November 29, 2018. San Diego, CA. [abstract] Blood. 2018; 132(Suppl 1):3539. doi: 10.1182/blood-2018-99-115613
Varadhachary GR, Spector Y, Abbruzzese JL, Rosenwald S, Wang H, Aharonov R, Carlson HR, Cohen D, Karanth S, Macinskas J, Lenzi R, Chajut A, Edmonston TB, Raber MN. Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary. Clin Cancer Res. 2011 Jun 15;17(12):4063-70. doi: 10.1158/1078-0432.CCR-10-2599